First‐in‐man study of ACT‐453859, a potent CRTH2 antagonist—Is the metabolite formation influenced by a polymorphic enzyme?

@article{Srinivas2015FirstinmanSO,
  title={First‐in‐man study of ACT‐453859, a potent CRTH2 antagonist—Is the metabolite formation influenced by a polymorphic enzyme?},
  author={N. Srinivas},
  journal={The Journal of Clinical Pharmacology},
  year={2015},
  volume={55}
}
  • N. Srinivas
  • Published 2015
  • Medicine
  • The Journal of Clinical Pharmacology
  • Gehin et al (2015) reported an interesting phase 1 investigation of ACT-453859, a new and potent CRTH2 antagonist, where a systematic evaluation of safety, tolerability, pharmacokinetics, and pharmacodynamics was performed in a meticulous manner. This has led to nominating the drug for the next phase of clinical investigation to probe the clinical effectiveness of the drug. The work needs to be commended for providing an exemplary early investigation package that could serve as a model to probe… CONTINUE READING

    Topics from this paper

    References

    A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects
    • 15